Phase I study of LY2181308, an antisense oligonucleotide against survivin, in patients with advanced solid tumors

Authors:

Abstract
LY2181308 is an antisense oligonucleotide that complementarily binds to survivin mRNA and inhibits its expression in tumor tissue. This phase I dose escalation study evaluated the tolerability, pharmacokinetics, and anticancer activity of LY2181308 in Japanese.

This publication has 20 references indexed in Scilit: